OPKO Health, Inc. (NASDAQ:OPK) (“OPKO” or “the
Company”) announces that GeneDx will be showcasing its leadership
in genetic and genomic testing with more than 35 poster and
platform presentations at the National Society of Genetic
Counselors (NSGC) and the American Society of Human Genetics (ASHG)
annual meetings this fall.
At the 36th Annual National Society of Genetic Counselors
Meeting taking place September 13-16 in Columbus, Ohio, GeneDx
will be presenting original scientific work and participating in
ancillary educational sessions. GeneDx has been selected by NSGC to
present data in three platform and 19 poster presentations. In
addition, GeneDx will be participating in two pre-conference
symposia and will be sponsoring an educational lunch session where
GeneDx experts will discuss how techniques such as next-generation
sequencing can be optimally leveraged as an important tool in
genetic variant detection and analysis. A complete listing of
GeneDx’s events at NSGC 2017 are available here, or if attending,
at booth #314.
At the American Society of Human Genetics Annual
Meeting taking place October 17-21 in Orlando, GeneDx will
present research in one podium and twenty poster presentations.
GeneDx is also a collaborator on six additional
presentations. A complete listing of GeneDx’s events at ASHG 2017
will be available on our website, or if attending, at booth
#654.
“GeneDx continues to demonstrate active engagement with the
clinical and scientific community in all aspects of genetic and
genomic testing, and we are excited to have been selected to share
our robust data and research with the larger genetics community,”
said Ben Solomon, MD, FACMG, Managing Director of GeneDx. “Our
prominent presence at the NSGC and ASHG meetings this fall
underscores the passion our entire team has for contributing to and
advancing the field of genomic medicine.”
In addition to participating in this year’s premier fall
genetics conferences, GeneDx is also excited to announce the
increased flexibility of its sample collection. GeneDx will now
offer the option of a U.S. Food and Drug Administration cleared
buccal (cheek swab) sample collection kit, which is available for
GeneDx’s expansive test menu and patients of any age.
“We are always looking at ways to make providers’ jobs easier,
and we will continue to invest in efforts that will help us meet
this goal,” said Sean Hofherr, PhD, FACMG, Chief Scientific Officer
at GeneDx.
To learn more about these new test kits or to receive kits in
your office, please contact a local GeneDx genetic testing
representative or visit the GeneDx website at www.genedx.com.
About GeneDxGeneDx is a world leader in
genomics with an acknowledged expertise in rare and ultra-rare
genetic disorders, as well as one of the broadest menus of
sequencing services available among commercial laboratories.
Providing testing to patients and their families in more than 55
countries, GeneDx is a business unit of BioReference Laboratories,
a wholly owned subsidiary of OPKO Health, Inc. To learn more,
please visit www.genedx.com.
To learn more about GeneDx’s complete list of testing offerings,
please visit www.genedx.com or email zebras@genedx.com. Follow
along on Twitter at @GeneDx and become a Facebook fan at @GeneDxLab
to get real-time updates!
About OPKO Health OPKO Health is a diversified
healthcare company that seeks to establish industry leading
positions in large, rapidly growing markets. Our diagnostics
business includes Bio-Reference Laboratories, the nation's
third-largest clinical laboratory with a core genetic testing
business and a 400-person sales and marketing team to drive growth
and leverage new products, including the 4Kscore® prostate cancer
test and the Claros® 1 in-office immunoassay platform. Our
pharmaceutical business features RAYALDEE, an FDA-approved
treatment for SHPT in stage 3-4 CKD patients with vitamin D
insufficiency (launched in November 2016), VARUBI™ for
chemotherapy-induced nausea and vomiting (oral formulation launched
by partner TESARO and IV formulation pending FDA approval),
OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes
and obesity which is a clinically advanced drug candidate among the
new class of GLP-1 glucagon receptor dual agonists, OPK88004, a
SARM (Selective Androgen Receptor Modulator) for treating BPH
(Benign Prostatic Hypertrophy), OPK88002, a NK-1 antagonist to
treat pruritus ( itching) in dialysis patients, and OPK88001, a
proprietary oligonucleotide to treat Dravet syndrome. In addition,
the Company is advancing its CTP technology, which includes long
acting hGH-CTP, a once weekly human growth hormone injection (in
phase 3 and partnered with Pfizer), and long acting Factor VIIa
drug for hemophilia in phase 2a. OPKO also has production and
distribution assets worldwide, multiple strategic investments and
an active business development strategy. More information available
at www.opko.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking statements," as
that term is defined under the Private Securities Litigation Reform
Act of 1995 (PSLRA), which statements may be identified by words
such as "expects," "plans," "projects," "will," "may,"
"anticipates," "believes," "should," "intends," "estimates," and
other words of similar meaning, including statements regarding
expected developments in our genetic testing, financial
performance, and the market for and sales of our products, our
product development efforts and the expected benefits of our
products, as well as other non-historical statements about our
expectations, beliefs or intentions regarding our business,
technologies and products, financial condition, strategies or
prospects. Many factors could cause our actual activities or
results to differ materially from the activities and results
anticipated in forward-looking statements. These factors include
those described in our Annual Reports on Form 10-K filed and to be
filed with the Securities and Exchange Commission and in our other
filings with the Securities and Exchange Commission. In addition,
forward-looking statements may also be adversely affected by
general market factors, competitive product development, product
availability, federal and state regulations and legislation, the
regulatory process for new products and indications, manufacturing
issues that may arise, patent positions and litigation, among other
factors. The forward-looking statements contained in this press
release speak only as of the date the statements were made, and we
do not undertake any obligation to update forward-looking
statements. We intend that all forward-looking statements be
subject to the safe-harbor provisions of the PSLRA.
Company OPKO Health, Inc. David Malina, 305-575-4100 Investor
Relationsdmalina@opko.com GeneDxJustin Leighton, MS, CGCClinical
Marketing Manager, 301-519-2100 x8141 jleighton@genedx.com
LHA Anne Marie Fields, 212-838-3777 afields@lhai.com or Bruce
Voss, 310-691-7100 bvoss@lhai.com
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2024 to May 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From May 2023 to May 2024